NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

There’s a more recent interview of Dr. Brem by Al Musella from a few months ago. He discusses advances in brain mapping, emerging imaging technologies, and various on-going trials and treatments including immunotherapies, but doesn’t mention DCVax until the Q & A at the end. (~32:20 minute mark) But really nothing new.

Presented 5/3/2020 as part of the Musella Foundation Brain Tumor Awareness Month Webinar Series:

Innovations in Brain Tumor Treatments by Stephen Brem

Here’s a transcript of the relevant bit:

Al Musella
You had a graph that showed the 5-year survival rate for all brain tumors. Do you have one just for GBM?

Dr. Brem
What we’re seeing in the (O U ?) study, and the DCVAX study of Linda Liau, and the Lomustine study, many studies, that there is a significant tail, so it’s quite binary. There are a significant percentage of long term survivors. So I hate to give a round number because (? ) so I try to stay away from that, especially in an audience of this sort.

Al Musella
It’s funny that you mention DCVAX, because we have a bunch of questions about DCVAX. Do you have any idea of when the final results are going to be presented? About? Because they keep telling us in two or three months, but they’ve said that for like the last year.

Dr. Brem
That’s a good question. Um, I’m lucky to be on the steering committee, but I’m not, I don’t know exactly. I, I know that they’re working on that, and it is imminent. And I haven’t seen the final results. As you know, it’s a tricky trial statistically because of the crossover rate.

Al Musella
Right. That was actually the next question. Is it even possible to get FDA approval when the trial was designed in that way where you do have the crossover?

Dr. Brem
I think that’s a great question. About 90 percent of the patients on the trial as you know, received either upfront, or on the crossover, so teasing that out, it’s not a classical randomized controlled trial that’s for sure. But we did publish in the Journal of Translational Research that there were a significant number of long term survivors. They’re looking at radiological markers. We do need a better biomarker that would really make all these trials to be more meaningful and be able to stop an effective trial, be able to accelerate effective when we see effective.